NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Legend Biotech Corporation (LEGN) Stock Analysis

Legend Biotech Corporation (LEGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LEGN

$21.52

−$0.23 (−1.06%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LEGN with… →

LEGN Key Statistics

As of Sep 4, 2026
Trading
Open
$21.52
Previous Close
$21.75
Day's Range
21.41–21.90
52-Week Range
16.24–37.50
Volume
812.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.40
Valuation
Market Cap
$4.19B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.93
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.29
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.49
Financials (FY)
Revenue (FY)
$1.03B+64.02%
Net Income (FY)
−$296.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.20%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
194.49M
1-Year Return
−38.50%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
2.43M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LEGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−1.01%
2025−33.19%
2024−45.92%
2023+20.53%
2022+7.10%
2021+65.52%
2020 (partial year)−23.89%

As of September 4, 2026.

LEGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.03B−$296.80M−28.8%
2024$627.30M−$177.00M−28.2%
2023$285.10M−$518.30M−181.8%
2022$117.01M−$446.35M−381.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.03B$620.80M−$136.50M−$296.80M−28.8%
2024$627.30M$392.70M−$309.50M−$177.00M−28.2%
2023$285.10M$140.90M−$528.10M−$518.30M−181.8%
2022$117.01M$51.64M−$455.62M−$446.35M−381.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LEGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricLEGNBiotechnology medianvs median
P/S ratio3.2915.260.2x the median
Profit margin−7.20%0.00%7.2 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Legend Biotech Corporation (LEGN) at $4.19B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 3,200 employees.

Over the past 52 weeks the price has ranged from $16.24 to $37.50. The most recent close on file for LEGN is $21.52, dated September 4, 2026. That is −$0.23 (−1.06%) against the previous close. The latest close sits 32.51% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.03B. Against the prior fiscal year total of $627.30M, that is a change of +64.02%. The same year closed with a net loss of $296.80M. Profit margin runs at −7.2%. That is 7.2 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.49.

Across the 4 fiscal years on file, revenue moves from $117.01M in 2022 to $1.03B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 19.93. Measured against sales, the shares trade at 3.29 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.4. Annualized volatility over the trailing 6 years is 56.62%. Over the trailing twelve months the price has returned −38.50%. Measured over 5 years, that is −11.18% a year compounded.

Growth & Income

No dividend is on file for LEGN.

Across the complete calendar years on file, 2021 returned +65.52% and 2024 returned −45.92%. Of the 5 complete calendar years on file, 3 finished higher. So far in 2026 the price is −1.01%.

Peer Comparison

Legend Biotech Corporation (LEGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Legend Biotech Corporation LEGN $4.19B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Legend Biotech Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Legend Biotech Corporation

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Visit website →